Valbiotis SA (FRA:8JD)

Germany flag Germany · Delayed Price · Currency is EUR
0.682
+0.003 (0.44%)
Last updated: Dec 5, 2025, 8:16 AM CET
-49.48%
Market Cap 16.75M
Revenue (ttm) 474.00K
Net Income (ttm) -11.12M
Shares Out n/a
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 662
Open 0.682
Previous Close 0.679
Day's Range 0.682 - 0.682
52-Week Range 0.527 - 1.604
Beta n/a
RSI 48.69
Earnings Date Dec 29, 2025

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laborato... [Read more]

Industry Pharmaceutical Preparations
Founded 2014
Employees 44
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8JD
Full Company Profile

Financial Performance

In 2024, Valbiotis's revenue was 176,000, a decrease of -96.28% compared to the previous year's 4.73 million. Losses were -10.03 million, 36.1% more than in 2023.

Financial Statements

News

There is no news available yet.